`LINGUAL
`
`CROSSLINGUAL, LLC
`3736 Fallon Road, Suite 226
`Dublin, CA 94568
`Tel: 206-851-7932
`hr@c|ingual.com
`
`AFFIDAVIT OF TRANSLATION
`
`I, Alan F. Siegrist, of CROSSLINGUAL, LLC, hereby declare that:
`1.
`I am fluent in Japanese and English.
`2.
`I am an active member of the American Translators Association and a Certified
`
`Translator of Japanese to English.
`
`3. The English translation attached to this declaration is an accurate and correct
`translation of the following document, attached hereto:
`2000.5 - 1st Edition [Bronuck Package Insert]
`I declare that the foregoing is true and correct to the best of my knowledge.
`
`Executed on October 29, 2015
`
`Alan F. Siegrist, CT
`CROSSLINGUAL, LLC
`ATA Member No. 31889
`Certification #63788
`
`A notary public or other officer completing this certificate verifies only the identity of the individual who signed the
`documents to which this certificate are attached, and not the truthfulness, accuracy, or validity of that document.
`
`5
`State of California, County of C:7!\+nl
`god1'/Let‘
`GfiV&“'\0;
`On l
`Q0‘ 5
`before me,
`who proved to me on the basis of satisfactory
`.
`personally appeared a ‘
`/l
`evidence to be the person whose name IS subscribed to the within instrument and acknowledged to me
`that he executed the same in his authorized capacity, and that by his signature on the instrument the
`
`Q
`
`-
`
`person, or the entity upon behalf of which the person acted, executed the Instrument.
`
`I certify under PENALTY OF PERJURV under the laws of the State of California that the foregoing
`paragraph is true and correct.
`
`Witness my hand and official seal.
`
`Signature
`
`PAGE 1 OF 5
`
`SENJU EXHIBIT 2111
`
`LUPIN V SENJU
`
`IPR20l5—0ll05
`
`
`
`May 2000 — Created (New Format, First Edition)
`
`Storage Method: Room temperature storage
`lkpirationz
`Tobeusedbytheelqrirationdatedisplayedontheexteriorpadtage
`(evenbelixeexpiratiorgtobeusedpromptlyafieropening).
`
`Japan Standard Commodity Classification No. 871319
`21200AMZ00168
`
`1997
`
`2000
`
`J
`I
`
`Non-steroidal anti-inflammatory ophthalmic agent
`
`Designated Prescription Drug BRONUCKO OPHTHALMIC SOLUTION
`Bromfenac sodium hydrate ophthalmic solution
`
`
`
`.2B
`
`
`
`The following adverse efl'ects were observed in the foregoing
`o
`
`s
`
`lepharitis, conjunctival hyperemia, stinging, ocular pain
`(temporary), corneal inflammation, corneal epithelial abrasion
`superficial punctate keratitis, follicular conjunctivitis, pruritus,
`andburnin sensation
`'ds
`
`When manifested. administration is suspended.
`3. Administration to Pregnant, Parturient, and Nursing
`Women
`
`Administration is to be conducted to pregnant woman or
`women who may have conceived and to women who are
`nursing only when it is judged that the benefits of treatment
`outweigh the risks.
`(The safety of administration during pregnancy and lactation
`has not been established.)
`4. Administration to Children
`
`Safety relative to children has not been established (there is
`little experience with use).
`5. Cautions for Use
`
`[Contraindications (do not administer to the following
`patients)]
`Patients with a previous history ofhypersensitivity to the
`in dients ofthis dru
`Co osition/Pro rties
`
`Ingediiinislgf
`
`Additives
`
`t Bromfenac sodiumllydrate 1 mg
`Boric acid, borax, dry sodium sulfite, sodium
`edetate, povidone, polysorbate 80,
`bennlkonium chloride
`
`Aqueous ophflralmic solution
`
`‘E:
`mam
`[Efficacy / Effects]
`Symptomatic treatment of inflammatory ailments of the
`external eye and anterior eye (blepharitis. conjunctivitis.
`episcleritis).
`postoperative
`scleritis
`(including
`and
`inflammation)
`[Usage I Dosage]
`Ordinarily. 1-2 drops per administration. and 2 ocular
`instillations per day.
`[Cautions for Use]
`1. Important Basie Cautions
`(1) Keeping in mind that treatment by this drug is symptomatic
`treatment rather than causal
`treatment. and that
`it
`is
`reported that serious liver damage (including death) has
`been
`observed
`in patients
`subjected
`to
`long-term
`administration of 1 month or more with the oral agent of
`bromfenac sodium. continuous administration for 4 weeks
`
`or more is not conducted in principle. Although the
`aforementioned adverse elfects observed with the foreign
`oral agent were due to long-term administration exceeding
`the approved usage and dosage. sales have been voluntarily
`suspended.
`(2) As there is risk that eye infection may become subclinical.
`in case of use on inflammation resulting from infection.
`administration is to be conducted carefully with adequate
`observation.
`2. Adverse Effects
`
`At the time of approval. adverse eflects had been observed in
`16 out of a total of 423 cases (3.78%).
`With respect to the content of adverse effects. there were
`3 cases of blepharitis
`(0.71%).
`3
`cases of conjunctival
`hyperemia (0.71%). 3 cases of stinging (0.71%). 3 cases of
`'
`(temporary)
`(0.71%).
`2 cases of
`corneal
`inflammation (0.47%).
`1 case of conical epithelial abrasion
`(0.24%). 1 case of superficial punctate keratitis (0.24%). 1 case
`of follicular conjunctivitis (0.24%). 1 case of pruritus (0.24%).
`and 1 case of burning sensation (eyelids) (0.24%) (at the time of
`approval).
`
`PAGE 2 OF 5
`
`(1) Administration route: only to be used for ocular instillation
`(2) At time of administration: during ocular instillation. take
`care so that the lip of the container does not directly contact
`the eye.
`[Pharmacokinetics]
`(Reference)
`Intraoeular Migration <rabbits>l)
`In testing wherein ocular instillation of 0.05 mL of 0. 1% “C-
`bromfenac sodium hydrate ophthalmic solution was conducted
`once a day is both eyes of rabbits. and radioactivity was
`measured after 15 minutes. 30 minutes. and 1. 2. 4. 8. 32. 24.
`48. and 72 hours. elevated values were observed in the cornea.
`conjunctiva. and anterior sclera.
`At 72 hours after ocular instillation. all ocular tissue except
`for the lens was below the detection limit (0.1 ng eq./g or
`mg 5: rgr'mt',
`I0‘
`0--‘Corina
`«j.. . .3
`'Conjum:tiva
`‘Anteriorsclera
`'AntuIorvltreouslmlmr
`.B1ood
`
`
`
`
`
`
`
`Bromfenacsodiumhydrateconcentration
`
`
`
`[Principal Literature]
`1) Mitsuyoshi Isaka et al.: Pharmacokinetics, 14 (1) 32, 1999
`2) Takahiro Ogawa et al.: Journal of Japan Ophthalmology Society, 99, 406, 1995
`[Contact for Requesting Literature]
`Scientific Information Department
`Senju Pharmaceutical Co., Ltd.
`5-8, Hirano-machi 2-chome, Chuo-ku, Osaka-shi, Osaka
`
`Marketed by: Takeda Pharmaceutical Co., Ltd.
`
`1-1, Dosho-machi 4-chome,
`
`Chuo-ku, Osaka
`
`Package 00-009
`
`
`
`
`
`
`
`
`
`Efficacy rate (%) and
`effectiveness
`66.7 (6/9)
`63.2 (60/95)
`63.6 (7/11)
`86.4 (152/176)
`77.3 (225/291)
`
`relative
`
`to
`
`experimental
`
`[Clinical Results]
`A summary of results with respect to 291 cases including
`double-blind comparative testing are shown in the table.
`For the most part, daily dosage and administration period
`were 1 drop per administration and 2 administrations per day
`over a 2-week period.
`Table. Clinical Effects by Ailment
`Name of ailment
`Blepharitis
`Conjunctivitis
`Scleritis (including episcleritis)
`Postoperative inflammation
`Total
`[Pharmacoefficacy and Pharmacology]
`1. Pharmacological Action
`(1) Anti-inflammatory
`action
`conjunctival chemosis in rats2)
`It was observed that Bronuck ophthalmic solution exhibited
`anti-inflammatory action relative to experimental acute
`conjunctival chemosis in rats induced by arachidonic acid
`and carageenin.
`(2) Inhibitory effects relative to increases in aqueous humor
`protein concentration in rabbits after anterior chamber
`paracentesis or after laser irradiation2)
`It was observed that Bronuck ophthalmic solution almost
`completely inhibited increases in aqueous humor protein
`concentration in rabbits after anterior chamber paracentesis
`or after laser irradiation.
`2. Mechanism of Action
`In tests using rabbit iris-ciliary bodies2) and bovine seminal
`vesicles, it was confirmed that inhibitory action was exhibited
`against production of prostaglandin inflammatory mediators via
`cyclooxygenase (in vitro).
`[Physicochemical Findings Relative to Active Ingredients]
`Generic name:
`Bromfenac Sodium Hydrate (JAN)
`Chemical name:
`sodium 2-amino-3-(4-bromobenzoyl)
`phenylacetate sesquihydrate
`Molecular formula: C15H11BrNNaO3 · 1½ H2O
`Molecular weight: 383.17
`Structural formula:
`
`
`Properties:
`
`
`
`
`Bromfenac Sodium Hydrate is an odorless
`crystalline powder of yellow-orange color.
`It is freely soluble in water, soluble in
`methanol, slightly soluble in ethanol
`anhydride, and practically insoluble in
`acetonitrile or ether.
`
`[Packaging]
`5 mL × 10, 5 mL × 50
`
`
`
` Manufactured by: Senju Pharmaceutical Co., Ltd.
`
`
`5-8, Hirano-machi 2-chome,
`
`
`Chuo-ku, Osaka
`
`PAGE 3 OF 5
`
`
`
`20005l'3 5 H{’Fl4!Z(HrH‘uUYS 1 W1)
`
`‘4=".iHf5Hr?
`iii 1
`1!?
`fhllflfillfli I 9|-Q‘-‘I5: J2/J'<¢0i!Ulll0Jl§iV~lLlfEm’$‘£ C 1: (1'flJ|HUH‘H|’~J'C‘
`&o<b.mH&u&@#uMmTb:tL
`
`u 4<e:Iiv:sfii.::.m'Mr
`mflfiflzmmmmw
`45 mi #1 E
`2000415 5 M
`ii 7"»: an we
`20003-1 7 5
`[RI F5! % '12
`19974I-I 7 I1
`
`3EZ:‘-EH’ Ffitfififinfilflfil
`
`7'D1"'J’)7¢.§flE>‘?tE
`
`BRONUCK’OPHTHALM|C SOLUTION
`7'EJA71T9T I~ ‘J '91.: 7J<iF|J43;J ififlfifii
`
`[fi§(7fl0J.E.§‘|C|$?Q5b7.IL\Z é:))
`
`#m®mfluflL£&fim&fiE®&%mfi
`
`-I
`_ Am.
`fiflmgf
`
`iélnlw
`
`7UA71+7+FUflA$N%lm
`3:-ant.
`-1:-aft». fiizidtsutifiirt-r I~U-71.. 1
`-7'l~1'l2+l~')'7A. rKt'I~"/. rR')ww<—
`bso, Jfi{|;«<'/+F:L:v.:-71.
`
`A<fl.:.'.i.ll1UiIl
`1::
`iIi‘fI'.Kf'!li_
`—
`pH
`
`.U.’l*‘0)El'H’Fifll.1,l:3L!0).”»W‘E’C'§£&b ¢3;fl7‘.' ¥> 0)'C“i:?.>o
`
`|1Rfiii[-°i§‘E].
`llfififi. fillfiifillll. ilfllfifli.
`fififiM.fifiLE%$.Hfi£HfiE
`fififiiliflfl. Jfiiffia.
`;!>&F.!é[llB1&]
`
`7'J£)’5E:B‘1Lf.:ifi‘:N:t1. -f’i‘i€"13Il;1‘/3 C to
`
`3. H15. E19. 1§¥Ltlfi'\0>?5!!=:~
`lffflllitflfiL’Cb‘Z>5I5E‘nZV)#)Z>fiA71Z}"'f§§L'1‘0)
`
`Eilktzcstifzfi I-.a>14‘§tt»<1EI5-fitié klills tfilfién
`
`61M.*I:a).77-§’i'i'9“/3.: to
`
`[ti-t6‘ér1'£tZ:"§§?LrlW>&ifrz:r!fl<tz»zEé_>1£l:c1li{£:zlxcw
`&wd
`
`4. IJ\bE¥'\0>1=21-;~
`
`/1*’/{‘.§Fl.'.i‘-.f‘3‘?5’£r'4_~*‘l$l;tffi.\‘I’. L*cu.n;-u~(1sEfl1i:§wM«‘
`tcw).
`
`ma: - 320%)
`
`5. fifiuaaiifi
`
`%flE.’fiI$}}.()‘%ri'dER.‘.‘B0)$éi:Y=Z1fE#5é.%.0);tI#fi4!%Ef12Ellflfifié. ma
`
`m&5&n:fimmumA&m¢5;a°
`
`$2.
`
`fi&§E(J;6§iJl§3i’&'.’:.‘t‘.r). mwzail
`
`(F539: - Hill
`
`1Ifil1~ zirfi. 1H2 Ifil.¢.illE'3“Z.>o
`
`lfimimfifil
`
`Lzaazxwan
`
`m$mu;ammufiwm&?u&<Nfimmv&5
`
`:&u§fiL.it.%Etsw<.7uA71+
`7+rUvAmfium%1»HuhEM&4Ltm
`E-c:_§fi71~H¥Fti§(9Etv.¢:’.e’rtr)7)<;i2ar>¢;:nf;to>fi!
`
`fi#&6®f.fiMkLf4EWuLw%fi&5u
`fib&m:a.&£.flmw&nmuflm5ntL
`flmmwmufiflwmfi-mfiéflitfimfifiu
`
`;6$®f&6fi.E£mKH%&mmLTw6o
`
`mmmfi%fi&$%WmT6£%n#%6wf.fi%
`u;6fifinNLfmu5fiGcufl§&+fiufi
`w.fi§u&5¢5:aa
`
`zmfim
`
`$a%fwfifimwwMnwMMwwumWm#%w
`"33"L7:o
`
`mwmmfiu.mw&3wmnm.m&mm3wmm
`
`96).
`
`ifi|J&!i§é3f’1'-(0.71%). mum—iam31'-r-(0.71%). fly
`
`m&m2wmn%xmmLmwx1wmm%Lmmi
`Hmm&1wmmw.gmmm10mum.m¢m1
`
`er (0.24%).
`
`.!:&!é§[fl.t1Ia] 1 fl"(0.24%)'C'3)’) 2*; (§<?i£B#).,
`
`PAGE 4 OF 5
`
`(2)?! 5» I15 I
`
`;.*.»‘.!1R0>.‘: 5-:-. ?$£fi=0)5E9!E7b‘i‘fiI4%l§I:i!!h
`&~u~J:’)&:7‘r.x§fi'z;.:2:o
`
`(imam)
`(1% «E-)
`m*mfi<-7+H=)"
`rv+r#a>rI-imu:0.1%"c--/ux.7I-2-7+ F‘) -7A Mum .-.T.Huiti
`0.05mL’2 llW.I.'.(|1EL. 15. 30/1}. 1. 2. 4. 8. 12. 24. 48. 725%
`|IUffz(:fik!Hii‘if|a*&iH|J2i£Li;.wi&“C*a:t. ma. ¥’F.l£b’cU’:iiI.‘fl$6§IJm:
`Mintii-»:'<Lr.-..
`/)<xh'u1IP&5i%<“3‘r<f0>uH¥Ilfl&'El&tli|945‘#
`.r.‘.ill11fl272ll-HliJ'C-Izt.
`(0.lng eq./g or mL).U. l"”C'&>-) to
`(neoq./semi)
`
`
`
`
`
`Hi3E‘3l'L‘OC7"i-\)‘+H\lI>Cl\l.
`
`10'
`
`8
`
`--
`
`:9 3
`:35 ll
`ziaaumn
`ififll7!<
`:01:
`SE
`\\\\\\\\\ 2 1!flJIH$?I:lT
`n=3
`
`‘\
`
`.“ \
`4B(§I)
`
`
`
`
`IEEIWI
`14(1), 32.1999.
`1) #i27U3’:Eum :
`
`
`
`
`
`
`9$WfifimlH$Mfl$%%%£&w&w%h
`
`
`
`
`
`
`
`
`
`[Ifi%$fi}9 *-
`+%%%9a%9 fimmww
`
`
`
`
`
`
`
`
`
`=fiM9m&xmm$%E$Mm:TE5fi&%
`
`Tiv
`
`
`
`
`
`
`
`
`
`
`,%m79
`lfifimfil
`
`
`
`:m§mwm9wa%¢99wmwmom<mmmmwufima
`
`
`
`
`39v$aD”» 9
`~
`
`
`
`
`
`
`
`
`
`
`
`
`-75:15.
`1 El#’£'~3—ii‘ -v}’£'4’—J9]ll5Jtiki%I$&}7§‘1 lfillffih 1H 2 IE. 255
`mv&5°'
`
`
`
`
`
`a.fimmmm9%
`
`
`
`
`
`
`
`
`'9 9
`
`
`
`
`§:’l‘?Ifi§€
`
`
`
`
`
`
`W*’=<%>W1i A
`
`
`
`
`
`
`
`
`'
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`[Efi%E1 9
`
`
`%
`WA
`Lfiflfifi
`~7
`M5vb$§WfiE#EtfiT§fifififim”
`
`
`
`
`
`7U+v7flmfiufivbEfiH575#FV@mflfi%:
`
`
`wt:&%%m%fi%H§MKfiLfififiWm&fi?:t#
`
`
`
`
`
`%m5nrw&9_
`9
`--
`
`
`
`
`
`
`
`
`
`
`m¢&¥fiE$Wfi1up—fi—%fifi®%*§E%E%mu
`
`
`fiféflflfifi”
`_-
`-
`.
`
`
`
`
`Tpfv&fiMfifi¢#¥KEfiéfiE$%fiI@V—f—
`
`mwfiwfimfiaflfimmtaafigmwmtaaaflfim
`
`
`
`
`
`:57I'L'Cu\E:.,
`
`
`
`
`
`'
`_
`zfimfifi
`
`fi%¥M%¥fiW“&w¢&fi$&mmtafiK£mf;9?
`
`
`
`
`
`
`n%$9V+~€&fif57uz7Vfi>vy%®%fix?4
`
`
`z—a—$mmwfim9fi9:awwflsnrmaunwmm
`
`
`
`
`
`
`
`
`9
`
`9
`
`
`
`
`[fi§?)3fi‘fr:}'lEB§'sJ"¥)T$‘f|3$El'\J$l]E}
`~i’i4’>'5 Z'7'1:1A7:.*}'7'3'
`i~ 'J"JL~ 7k$II!I?J
`
`
`
`
`
`
`
`
`(Bromfenac Sodium Hydrate)
`[JAN]
`
`
`
`
`‘I|$‘-'3"<¥u I sodium 2-amino-3-(4-bromobenzoyl)phenylacetate
`
`
`
`sesquihydrate
`
`
`
`
`: C|5H11Bl‘NNa0n' 1%I-I20
`5}—T-it
`
`
`53~¥Et : 383.17 '
`9
`
`
`
`Wfifii
`fi-
`'
`
`' Br C '
`
`‘
`
`HZN
`
`
`
`cH,,c0,Na - la/2H,0 M
`
`
`
`_
`
`
`
`
`
`
`
`9 W:7UL71+9%bU6AmflWfi{fifi~fifi®fi&
`
`I::Bu~li7;w~o
`1¥6')?:‘5}3l£'C°.
`
`
`§.H£7.f<l
`7k&:2‘§n‘=<°'§r<. X5’/—)W:-‘i°’i°i€:‘1iJ‘-‘<°'3‘<.
`
`57 /—)vI:i*§§h‘L:< <9 7% Ix; 1~ I) :1/3u::_—7*-M:
`
`
`
`li.’_'/L:‘_"i'§:°-li'35?‘4‘o
`
`
`
`
`
`'
`
`-
`
`'
`
`
`
`
`la 951
`
`
`5mL x 10. 5mI:>< 50 T
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`9-2% :"etEeI§':9*.I%9t:-:t*=z:¢i--'
`?kHiiIiFF§&!Zififi'£|1lIlElTE HE1-3'
`
`
`
`
`€1.00 -009
`
`
`PAGESOFS
`
`PAGE 5 OF 5